By a News Reporter-Staff News Editor at Clinical Oncology Week -- FORMA Therapeutics announced that Duncan Walker, Ph.D., has been appointed to the position of Vice President, Pharmacology and Early Development. Dr. Walker joins FORMA after 20 years in the pharmaceutical and biotechnology sector, most recently at Array BioPharma (see also FORMA Therapeutics).
"Duncan's proven expertise in leading discovery, translational and early clinical development teams in oncology is an exemplary fit for FORMA, since we are now advancing a differentiated pipeline of programs into preclinical and early development," said Kenneth W. Bair, Ph.D., Chief Scientific Officer and Head of Research and Development at FORMA Therapeutics. "As a results-oriented leader having an emphasis on precision medicine, he is ideally suited to readily impact FORMA."
"I am proud to be joining FORMA, a team united in the relentless pursuit of innovative therapies to change lives," said Dr. Walker. "I look forward to applying my experience in oncology preclinical development to enable FORMA's success and deliver high quality medicines to patients."
Prior to joining FORMA, Dr. Walker led the Oncology, Cellular and Translational Medicine team at Array BioPharma and notably was responsible for advancing its ARRY-520 clinical program in multiple myeloma. Prior to that, he was Vice President, Discovery Biology at Sunesis Pharmaceuticals and Vice President, Oncology Research at Roche, and he also held various scientific and managerial leadership positions at Glaxo Wellcome. Dr. Whitney has co-authored 30 publications and patents and has served as a member of various scientific advisory boards. Dr. Walker received his Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis and was an HHMI Research Fellow at University of Colorado Health Science Center in Denver. About FORMA FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com Join our conversation on Twitter @FORMAInc.
Keywords for this news article include: Oncology, Chemicals, Chemistry, FORMA Therapeutics.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC